About UroMems
UroMems is a company based in Grenoble (France) founded in 2011. UroMems has raised $145.73 million across 7 funding rounds from investors including BNP Paribas, Crédit Agricole and Banque Populaire. UroMems offers products and services including UroActive. UroMems operates in a competitive market with competitors including Axonics, Amber Therapeutics, NeuSpera Medical, MyoPowers Medical Technologies and Levee Medical, among others.
- Headquarter Grenoble, France
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$145.73 M (USD)
in 7 rounds
-
Latest Funding Round
$60 M (USD), Series D
May 14, 2026
-
Investors
BNP Paribas
& 15 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of UroMems
UroMems offers a comprehensive portfolio of products and services, including UroActive.
Smart implant for treating severe stress urinary incontinence.
People of UroMems
Unlock access to complete
Unlock access to complete
Funding Insights of UroMems
UroMems has successfully raised a total of $145.73M across 7 strategic funding rounds. The most recent funding activity was a Series D round of $60 million completed in May 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in UroMems
UroMems has secured backing from 16 investors, including venture fund and institutional investors. Prominent investors backing the company include BNP Paribas, Crédit Agricole and Banque Populaire.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Long-term investments in startups are facilitated by this company.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Venture capital is provided to innovative startups by b2venture.
|
Locked | Locked | Locked |
Investor details for UroMems
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by UroMems
Investment portfolio details for UroMems
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - UroMems
Detailed financials for UroMems
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Uromems Comparisons
Peer comparison for UroMems
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of UroMems
UroMems operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Axonics, Amber Therapeutics, NeuSpera Medical, MyoPowers Medical Technologies and Levee Medical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Sacral neuromodulation devices are developed for urinary and bowel control.
|
|
| Locked | Locked | Locked |
Bioelectrical therapies for peripheral nervous system disorders are developed.
|
|
| Locked | Locked | Locked |
Miniaturized injectable neuromodulation devices are developed for chronic diseases.
|
|
| Locked | Locked | Locked |
An implantable device for the treatment of urinary incontinence stress
|
|
| Locked | Locked | Locked |
Urological devices for post-prostatectomy incontinence are developed by Levee Medical.
|
Detailed competitors of UroMems
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Uromems
Complete news archive for UroMems
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about UroMems
UroMems was founded in 2011 and raised its 1st funding round 5 years after it was founded.
UroMems is headquartered in Grenoble, France. It is registered at Grenoble, Auvergne-rhone-alpes, France.
UroMems is a funded company, having raised a total of $145.73M across 7 funding rounds to date.
Developer of active implantable devices for urological incontinence. The device MyoElectroMechanical System is based on a technology where a patients activity is measured in real-time through micro-sensors inside the implant into which algorithms are embedded; the system interprets data coming from the micro-sensors and computes the urethral pressure to apply.
UroMems's top competitors include Axonics, NeuSpera Medical and Amber Therapeutics.
UroMems offers UroActive.
UroMems has 16 investors. Key investors include BNP Paribas, Crédit Agricole, Banque Populaire, Caisse D Epargne, and European Commission.